BioLamina

Charlene Beier

🇧🇷 Brazil

9.1

Reviewed: April 6, 2024

• - HTA Submission
• - 8 weeks February - March 2024
• - Biotech Company

The HTA submission was comprehensive and well-executed. The team managed the complexities of the submission process expertly, ensuring that all necessary data was included and well-presented.

Sherri Murray

🇰🇷 South Korea

9.4

Reviewed: November 8, 2023

• - Health Technology Assessment
• - 10 weeks September - November 2023
• - Pharmaceutical Company

The health technology assessment was thorough and provided valuable insights that were critical to our decision-making process. The team demonstrated a deep understanding of the health economics involved and delivered a well-rounded analysis.

Bonnie Lemke

🇯🇵 Japan

5.8

Reviewed: April 5, 2024

• - Biostatistical Design
• - 6 weeks February - March 2024
• - Research Institution

The biostatistical analysis provided was not as thorough as we had hoped. Some key insights were missed, and we had to engage another provider to get the level of detail we needed. The team seemed overworked and under-resourced.

Mr. Cecil Gulgowski

🇮🇹 Italy

9.2

Reviewed: August 20, 2024

• - Regulatory Strategy Consulting
• - 4 weeks July - August 2024
• - Biotech Startup

The regulatory strategy consulting services were thorough and provided us with a clear pathway to regulatory approval. The team's deep understanding of the regulatory landscape was invaluable, and their strategic advice was spot on.

Bennie Herzog

🇨🇦 Canada

8.9

Reviewed: December 1, 2023

• - Medical Writing
• - 5 weeks October - November 2023
• - Biotech Company

The medical writing services provided were of top quality. The documents were clear, precise, and tailored to meet the specific requirements of our regulatory submissions. The team's expertise was evident throughout the process.

Lauren Hettinger

🇫🇷 France

9

Reviewed: February 4, 2024

• - Biomarker Development
• - 12 weeks October 2023 - January 2024
• - Research Institution

The biomarker development project was managed efficiently, with precise results that met our project objectives. The team's expertise in biomarker research was invaluable, and we were impressed with the quality of the deliverables.

Kim Yundt

🇦🇺 Australia

9.1

Reviewed: September 5, 2024

• - Pharmacovigilance Services
• - Ongoing
• - Pharmaceutical Company

The pharmacovigilance services ensured that our post-market surveillance was compliant and effective. The team was proactive in monitoring and reporting, providing us with peace of mind and ensuring patient safety.

Carl Kerluke

🇲🇽 Mexico

5.6

Reviewed: February 20, 2024

• - Clinical Data Management
• - 8 weeks December 2023 - February 2024
• - Biotech Company

The data management services were delayed, and communication from the team was lacking. It was difficult to get updates, and when the deliverables arrived, they were not as polished as expected. The delays impacted our project timeline significantly.